Imagyn to Acquire Tyco's Breast Biopsy Device

In a move to strengthen the company's position in the image-guided breast biopsy market, Imagyn Medical Technologies, Inc. (Irvine, CA, USA) has agreed to acquire the ABBI breast biopsy device from Tyco Healthcare Group (Pembroke, Bermuda). Terms were not disclosed.

Imagyn is the manufacturer and marketer of the SiteSelect breast biopsy system. Both SiteSelect and ABBI are disposable diagnostic devices used to obtain a tissue specimen of mammographically identified abnormalities in breast tissue. They are less invasive, time-consuming, and expensive than surgical biopsy and offer the advantage of capturing a single, contiguous specimen for pathologic analysis to increase accuracy. The biopsy is performed on an outpatient basis using local anesthesia.

"Our experience with SiteSelect has clearly demonstrated that large core stereotactic devices provide patients with biopsies that are relatively fast, cause little discomfort, if any, and offer a definitive diagnosis,” said Charles A. Laverty, chairman and CEO of Imagyn.





Related Links:
Imagyn
Tyco